SCHEMBL4841734

SCHEMBL4841734

CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1nc2ccccc2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.51
GPR119 Q8TDV5 3/20 0.48
HDAC1 Q13547 2/20 0.47
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
HSD11B1 P28845 1/20 0.43
ALDH1A1 P00352 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GRM2 Q14416 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PAX8 Q06710 1/20 0.39
LTA4H P09960 1/20 0.39
F13A1 P00488 1/20 0.38
TGM2 P21980 1/20 0.38
TGM1 P22735 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8104274 0.79 GPR119 (0.58) GPR119NPC1RAB9AALDH1A1MAPT
SCHEMBL24403118 0.78 PARP1 (0.44) PARP1GPR119HDAC1HSD11B1GRM2
SCHEMBL24403051 0.77 PARP1 (0.43) PARP1GPR119HDAC1HSD11B1GRM2
SCHEMBL30818801 0.77 PARP1 (0.54) PARP1GPR119HDAC1HSD11B1F13A1
SCHEMBL8111642 0.77 NPC1 (0.55) GPR119HDAC1NPC1RAB9AALDH1A1
SCHEMBL31254490 0.76 GPR119 (0.55) GPR119NPC1RAB9AALDH1A1MAPT
SCHEMBL1904449 0.76 LTA4H (0.46) PARP1GPR119RAB9AHSD11B1LTA4H
SCHEMBL13051178 0.76 LTA4H (0.48) PARP1GPR119HDAC1SMN1; SMN2LTA4H
SCHEMBL31283824 0.76 GPR119 (0.51) PARP1GPR119HDAC1HSD11B1GRM2
SCHEMBL4839260 0.75 CHRNA7 (0.47) NPC1RAB9AALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329754-B2 2,5-diazabicyclo[2.2.1]heptane derivatives NEUROSEARCH A/S (DK) 2008-02-12 US disclosed
EP-1368348-B1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH AS (DK) 2005-01-19 EP disclosed
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives DANPET AB (SE) 2004-09-16 US disclosed
EP-1368348-A1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2003-12-10 EP disclosed
WO-2002070522-A1 NOVEL 2,5-DIAZABICYCLO[2.2.1]HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives CHRNA2, CHRNB2, CHRNA10 PARP1 1579/4885GPR119 111/4885HDAC1 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.